Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Salix Pharmaceuticals has announced that, pursuant to a supply and distribution agreement, Watson Pharma will market and sell an authorized generic of Colazal capsules 750mg for the treatment of mildly to moderately active ulcerative colitis.
Subscribe to our email newsletter
Carolyn Logan, president and CEO, said: “Salix is committed to aggressively protecting its Colazal business and growing market share in the inflammatory bowel disease market. As part of our life cycle management program for Colazal, we are extremely pleased to partner with Watson to market and sell the authorized generic of Colazal. Watson is a major supplier of generic pharmaceutical products, and, with decades of experience and impressive expertise in the generics business, should be positioned to maximize our generic business.”